A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

Study Alias: I4T-MC-JVDA

The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus

Study Alias: I8F-MC-GPGB

The purpose of this study is to evaluate the efficacy of the study drug tirzepatide in participants with type 2 diabetes mellitus.

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

Study Alias: I3Y-MC-JPCB

The purpose of this study is to evaluate how abemaciclib interacts with a drug mixture containing caffeine, warfarin, dextromethorphan, and midazolam and how this interaction affects blood levels in the body.

A Study of LY900014 in Participants With Type 1 Diabetes Mellitus

Study Alias: I8B-MC-ITSA

The purpose of this study is to compare LY900014 with insulin lispro (Humalog) in participants with type 1 diabetes. There are 2 parts to this study. In Part A, the study treatment will be given by injection just under the skin (subcutaneously). In Part B, the study treatment will be given by an insulin pump.

A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Study Alias: I4T-JE-JVCW

The main purpose of this study is to evaluate the effectiveness of S-1 and oxaliplatin with or without ramucirumab as first line therapy in participants with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

A Study of Galcanezumab (LY2951742) in Participants with Cluster Headache

Study Alias: I5Q-MC-CGAR

The main purpose of this study is to assess the long-term safety and tolerability of galcanezumab administered up to once monthly in participants with episodic or chronic cluster headache who have completed study I5Q-MC-CGAL (NCT02397473) or study I5Q-MC-CGAM (NCT02438826).

A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease (SERENITY)

Study Alias: I6T-MC-AMAG

The purpose of this study is to evaluate the safety and effectiveness of the study drug LY3074828 in participants with active Crohn's Disease.

A Study of LY3502970 in Participants With Type 2 Diabetes

Study Alias: J2A-MC-GZGC

The main purpose of this study is to learn more about the safety of LY3502970 and any side effects that might be associated with it. Blood tests will be done to measure how much LY3502970 is in the bloodstream, how long it takes the body to eliminate it, and how it affects blood sugar.

A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes.

Study Alias: I8B-MC-ITSZ

The reason for this study is to evaluate the amount of time with glucose values within target range.

A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer

Study Alias: J1E-MC-JZEA

The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3434172, a PD-1/PD-L1 bispecific antibody, in participants with advanced solid tumors.

A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy

Study Alias: I8B-FW-ITRH

The study will to investigate how the body processes LY900014 and the effect of LY900014 on blood sugar levels in participants with type 2 diabetes on insulin injection therapy. Side effects and tolerability will be documented.

A Study of LY3022855 In Participants With Breast or Prostate Cancer

Study Alias: I5F-MC-JSCB

The main purpose of this study is to learn more about how the investigational drug, LY3022855, affects the immune system in participants with advanced breast or prostate cancer that has not responded to other treatments. Treatment may last up to 6 cycles (cycle = 6 weeks).

A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a CGRP Antagonist

Study Alias: I5Q-MC-CGBC

The purpose of this study is to measure the gastrointestinal emptying time using the wireless motility capsule (WMC) technology (FDA approved SmartPill™) in adult participants with migraine who are taking a calcitonin gene-related peptide (CGRP) antagonist called Galcanezumab or Erenumab.

A Study of LY3471851 in Participants With Psoriasis

Study Alias: J1P-MC-KFAC

The main purpose of this study is to learn more about the safety and side effects of LY3471851 when given by injection just under the skin to participants with psoriasis.

A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

Study Alias: H6D-MC-LVHV

The main purpose of this study is to evaluate the safety and efficacy of tadalafil in pediatric participants with pulmonary arterial hypertension. Participants will receive study treatment for 6 months in the double-blind period (Period 1), and then will be eligible to enroll into an open-label 2 year extension period (Period 2) during which participants will receive tadalafil.

A Study of LY3023414 and Necitumumab in Participants With Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Study Alias: I6A-MC-CBBE

The main purpose of this study is to evaluate the safety and activity of the study drug known as LY3023414 in combination with necitumumab in participants with metastatic squamous non-small cell lung cancer (NSCLC).

A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis (COAST-V)

Study Alias: I1F-MC-RHBV

The main purpose of this study is to evaluate the safety and efficacy of the study drug known as ixekizumab in participants with radiographic axial spondyloarthritis (rad-axSpA) who have never taken biological disease-modifying anti-rheumatic drugs (bDMARDs).

A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

Study Alias: I1F-MC-RHBE

The main purpose of this study is to evaluate how effective and safe the study drug known as ixekizumab is in participants with active psoriatic arthritis.

A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

Study Alias: I2V-MC-CXAD

The main purpose of this study is to evaluate the safety and tolerability of chemokine (C-X-C Motif) receptor 4 (CXCR4) peptide antagonist LY2510924 and durvalumab for phase 1a and 1b in participants with advanced refractory solid tumors.

A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

Study Alias: I8F-JE-GPGP

The purpose of this study is to determine the long-term safety of the study drug tirzepatide in combination with oral antihyperglycemic medications in participants with type 2 diabetes.

A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC

Study Alias: I4X-MC-JFCP

The purpose of the study is to determine if nab-paclitaxel and carboplatin chemotherapy plus necitumumab is effective and safe in participants with stage IV squamous non-small cell lung cancer.

A Study of LY3154207 in Participants With Parkinson's Disease (Part B)

Study Alias: I7S-EW-HBEC

The purpose of part B of this study will evaluate how safe LY3154207 is and the effect it has on the body.

A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes (PRONTO-Pump)

Study Alias: I8B-MC-ITSI

The purpose of this study is to evaluate the compatibility and safety of LY900014 and insulin lispro with an insulin pump in adults with type 1 diabetes.

A Study of Tirzepatide in Participants With Impaired Liver Function

Study Alias: I8F-MC-GPGQ

The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired liver function compared to healthy participants.

A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy

Study Alias: H9X-MC-GBGJ

The purpose of this study is to evaluate the efficacy and safety of investigational doses of dulaglutide in participants with type 2 diabetes on metformin monotherapy.

A Study of LY3127804 with Ramucirumab in Participants with Advanced Solid Tumors

Study Alias: I7W-MC-JQBA

The main purpose of this study is to evaluate the safety of the study drug known as LY3127804 given as monotherapy and in combination with Ramucirumab for participants with advanced or metastatic solid tumors. The study will also include a safety exploration for the combination of LY3127804 plus ramucirumab and paclitaxel.

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis (IXORA-P)

Study Alias: I1F-MC-RHBP

The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis

A Study of LY3209590 in Participants With Type 2 Diabetes

Study Alias: I8H-MC-BDCB

This study will evaluate the safety and tolerability of LY3209590 when given by injection under the skin to participants with type 2 diabetes. It will also investigate how the body processes the study drug and the effect of the study drug on blood sugar levels.

A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis (COAST-X)

Study Alias: I1F-MC-RHBX

The main purpose of this study is to evaluate the safety and efficacy of the study drug known as ixekizumab in biologic disease modifying antirheumatic drug (bDMARD) naïve participants with nonradiographic axial spondyloarthritis (nonrad-axSpA).

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes (T2DM)

Study Alias: I8F-MC-GPGA

The 3 main purposes of this study are to determine the safety of tirzepatide and any side effects that might be associated with it, how much tirzepatide gets into the bloodstream and how long it takes the body to get rid of it and how tirzepatide affects the levels of blood sugar. Each participant will enroll in only one part. This study is for research purposes only, and is not intended to treat any medical condition.

A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)

Study Alias: I4V-MC-JAHH

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as baricitinib in participants with systemic lupus erythematosus.

A Study of LY2606368 in Participants With Advanced Cancer

Study Alias: I4D-EW-JTJG

The main purpose of this study is to evaluate the safety of the study drug known as LY2606368 in participants with advanced cancer or cancer that has spread to other parts of the body.

A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer

Study Alias: H9H-MC-JBEG

The main purpose of this study is to evaluate the safety and efficacy of the study drug known as galunisertib administered in combination with the anti-programmed cell death-ligand 1 (PD-L1) antibody, durvalumab, in participants with refractory metastatic pancreatic cancer.

A Study of LY3041658 in Participants With Skin Diseases

Study Alias: I7P-MC-DSAB

The main purpose of this study is to investigate the safety and tolerability of the study drug known as LY3041658 in participants with certain types of skin diseases. The study will measure how the body absorbs, breaks down and gets rid of LY3041658.

A Study of LY3076226 in Participants With Advanced or Metastatic Cancer

Study Alias: I7O-MC-JOBA

The main purpose of this study is to evaluate the safety of the study drug known as LY3076226 in participants with advanced or metastatic cancer.

A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma

Study Alias: I5B-MC-JGDM

The purpose of this study is to evaluate potential biomarkers and method of action, efficacy and safety of olaratumab in participants with soft tissue sarcoma (STS).

A Study of LY3113593 in Participants With Chronic Kidney Disease

Study Alias: I7C-MC-FEAC

The purpose of this study is to determine the safety of the study drug, LY3113593. The study will also evaluate how much of the study drug gets into the blood stream, how long it takes the body to remove the study drug, and what effect the study drug has on the body. This study is not intended to treat anemia of chronic kidney disease. Participants will receive up to four injections of LY3113593 or placebo into a vein.

A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis

Study Alias: I4V-MC-JAHG

The purpose of this study is to evaluate the safety and effectiveness of baricitinib in people with eczema.

A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer

Study Alias: I3Y-MC-JPBX

The main purpose of this study is to evaluate the effectiveness of the study drug known as abemaciclib versus docetaxel in participants with stage IV squamous non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy.

A Study of LY2951742 in the Prevention of Episodic Migraine (EVOLVE-1)

Study Alias: I5Q-MC-CGAG

The main purpose of this study is to evaluate the efficacy of the study drug known as LY2951742 in participants with episodic migraine.

A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

Study Alias: I8F-MC-GPGI

The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to placebo in participants with type 2 diabetes that are already on insulin glargine, with or without metformin. Participants will administer tirzepatide or placebo along with their previous glucose lowering medications.

A Safety Study of LY2951742 in Participants With Migraine, With or Without Aura

Study Alias: I5Q-MC-CGAJ

The main purpose of this study is to evaluate the longer term safety of the study drug known as LY2951742 in participants with episodic or chronic migraine

A Study of LY2951742 in Participants With Chronic Cluster Headache

Study Alias: I5Q-MC-CGAM

The main purpose of this study is to evaluate the efficacy of the study drug known as LY2951742 in participants with chronic cluster headache.

A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

Study Alias: H6D-MC-LVIG

The purpose of this study to evaluate the drug Tadalafil and how much of the study drug is in the blood after dosing in children with pulmonary arterial hypertension (PAH) and to establish the correct dose for further clinical research.

A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer

Study Alias: I5B-MC-JGDN

The main purpose of this study is to evaluate the safety of different doses of olaratumab and to determine which dose should be used for future pediatric studies. The present study is open to children with advanced cancer or cancer that has spread to another part of the body. The study has two parts. In each part, a specific dose of olaratumab will be given alone for 21 days and followed by one of three standard chemotherapy regimens. Participants will enroll in one part only.

A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

Study Alias: I4D-MC-JTJN

The purpose of this study is to evaluate the efficacy and safety of prexasertib in women with ovarian, primary peritoneal, or fallopian tube cancer that did not respond well to chemotherapy or has recurred.

A Study of Baricitinib (LY3009104) in Adults With Moderate to Severe Atopic Dermatitis (Eczema) (BREEZE-AD1)

Study Alias: I4V-MC-JAHL

The purpose of this study is to evaluate the efficacy and safety of baricitinib as a single drug treatment in participants with moderate to severe atopic dermatitis (eczema).

A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19

Study Alias: J2W-MC-PYAA

The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it.

A Study of LY3303560 in Participants with Mild Cognitive Impairment or Alzheimer's Disease

Study Alias: I8G-MC-LMDD

This study involves repeated doses of LY3303560 given by injection for 25 weeks. The study will examine how safe repeated doses of LY3303560 are, whether they cause side effects in participants with mild cognitive impairment or Alzheimer's Disease, and how LY3303560 is handled by the body and acts in the body.

A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis

Study Alias: I9H-MC-FFAA

The purpose of this study is to evaluate how well LY3316531 is tolerated and what side effects may occur in healthy participants and participants with psoriasis. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm).

A Study of Ixekizumab in Participants with Plaque Psoriasis

Study Alias: I1F-MC-RHBU

The purpose of this study is to learn about how ixekizumab may affect the blood levels of a mixture of commonly used drugs.

A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)

Study Alias: I6M-MC-SSAD

The main purpose of this study is to learn more about the safety and side effects of the study drug known as LY3090106 in participants with Sjögren's Syndrome (SS). The study will also evaluate how much of the study drug gets into the blood stream and how long it takes the body to remove it.

A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated with Idiopathic Parkinson’s Disease (PD) or Dementia with Lewy Bodies (DLB) (PRESENCE)

Study Alias: I7S-MC-HBEH

A randomized placebo-controlled trial to evaluate the safety and efficacy of three doses of study drug LY3154207 treated for 12 weeks in participants with mild-to-moderate dementia associated with LBD (PDD or DLB).

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

Study Alias: I8F-MC-GPGK

The goal for this study is to evaluate the efficacy and safety of tirzepatide versus placebo in participants with type 2 diabetes not under control with diet and exercise alone.

A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis

Study Alias: I4V-MC-JAIY

The purpose of this study is to evaluate the efficacy and safety of baricitinib in combination with topical corticosteroids (TCS) in participants with moderate to severe atopic dermatitis.

A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer (neoMONARCH)

Study Alias: I3Y-MC-JPBY

The purpose of this study is to evaluate the biological effects of abemaciclib in combination with anastrozole and compare those to the effects of abemaciclib alone and anastrozole alone in the tumors of postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative breast cancer.

An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants with Type 2 Diabetes Mellitus (VIVID)

Study Alias: B5K-MC-IBHD

The main purpose of this study is to evaluate the safety and efficacy of Human Regular U-500 Insulin Administered by Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Subjects With Type 2 Diabetes Mellitus

A Study of LY3039478 in Participants with Advanced Cancer

Study Alias: I6F-MC-JJCA

The purpose of this study is to find a recommended dose level of LY3039478 that can safely be taken by participants with advanced cancer or cancer that has spread to other parts of the body, including but not limited to lymphoma. The study will also explore changes to various markers in blood cells and tissue. Finally, the study will help to document any tumor activity this drug may have.

A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

Study Alias: I8H-MC-BDCM

The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes that have already been treated with basal insulin.

A Study of LY900014 in a Medtronic Pump

Study Alias: I8B-MC-ITSM

The purpose of this study is to compare the study drug LY900014 to insulin lispro (Humalog) when both are delivered by the Medtronic MiniMed 670G System in adults with type 1 diabetes (T1D). The study will consist of two treatment periods of 4 weeks.

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma that has Spread to the Brain

Study Alias: I3Y-MC-JPBO

The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as abemaciclib in participants with hormone receptor positive breast cancer, non-small cell lung cancer (NSCLC), or melanoma that has spread to the brain.

A Study Comparing LY900014 to Insulin Lispro in Adults With Type 1 Diabetes Using Insulin Pump Therapy

Study Alias: I8B-MC-ITRO

The reason for this study is to compare the study drug LY900014 to insulin lispro when both are used in insulin pump therapy in adults with type 1 diabetes (T1D).

A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome

Study Alias: F1J-MC-HMGW

The purpose of this study is to determine whether duloxetine is safe and effective in the treatment of adolescents with Juvenile Primary Fibromyalgia Syndrome (JPFS). This trial consists of two distinct study periods; a blinded treatment period of 13 weeks and an open label extension period of 26 weeks.

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

Study Alias: I8F-MC-GPGF

The purpose of this study is to determine the efficacy of tirzepatide in participants with type 2 diabetes.

A Study of LY3202328 in Overweight Healthy Participants and in Participants With Dyslipidemia

Study Alias: I8Q-MC-GSEA

The purpose of this two-part study is to evaluate the safety and tolerability of the study drug known as LY3202328 in healthy overweight participants in Part A, and those with dyslipidemia (abnormal blood fats) in Part B.

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus (Award-10)

Study Alias: H9X-MC-GBGE

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as dulaglutide when added to sodium-glucose co-transporter 2 (SGLT2) inhibitors in participants with type 2 diabetes mellitus

A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer

Study Alias: I4D-MC-JTJH

The purpose of this study is to evaluate the safety and efficacy of prexasertib when given to participants with extensive stage disease small cell lung cancer (ED-SCLC). The study will evaluate how the body processes the drug and how the drug affects the body. The study will also evaluate the association between tumor response and the participant's perceived quality of life.

A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis (Eczema) (BREEZE-AD5)

Study Alias: I4V-MC-JAIW

The purpose of this study is to evaluate the efficacy and safety of baricitinib in adult participants with moderate to severe eczema.

A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis (SPIRIT P3)

Study Alias: I1F-MC-RHBF

The main purpose of this study is to evaluate the safety and long-term efficacy of ixekizumab compared to placebo in participants with active psoriatic arthritis.

A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer

Study Alias: I4T-MC-JVCU

The main purpose of this study is to evaluate the effectiveness of ramucirumab, which is a targeted antibody, in combination with capecitabine and cisplatin compared to capecitabine and cisplatin alone in participants with stomach cancer.

A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

Study Alias: I4T-MC-JVDK

The main purpose of this study is to evaluate the safety of ramucirumab (LY3009806) in combination with other targeted agents in participants with advanced cancers.

A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)

Study Alias: I8G-MC-LMDA

The purpose of this study is to evaluate the safety and tolerability of the study drug, LY3303560, administered either intravenously or subcutaneously, in both healthy participants and patients with Alzheimer's disease. Side effects and laboratory results will be monitored.

A Study of Necitumumab (LY3012211) and Abemaciclib (LY2835219) in Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)

Study Alias: I4X-MC-JFCU

The purpose of this study is to evaluate the safety and efficacy of two new medicines, (Necitumumab and Abemaciclib), administered in combination in participants with advanced lung cancer (stage IV non-small-cell lung cancer).

A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer

Study Alias: I4D-MC-JTJL

The main purpose of this study is to evaluate the safety of the study drug prexasertib in combination with ralimetinib in participants with advanced or metastatic cancer.

A Study of Mirikizumab in Participants With Plaque Psoriasis

Study Alias: I6T-MC-AMBP

This study is known as a "drug interaction study." The purpose is to learn how commonly used drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and their breakdown products get into the bloodstream after taking a "cocktail" (combination) of them before and after multiple doses of mirikizumab. The study will last about 23 weeks for each participant. Screening must be completed within 4 weeks prior to study start.

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

Study Alias: I4D-MC-JTJF

The main purpose of this study is to investigate the safety of prexasertib in combination with other anti-cancer drugs (cisplatin, cetuximab, pemetrexed, fluorouracil or LY3023414) in participants with advanced cancer or cancer that has spread to another part of the body. The study has multiple parts (A, B, C, D and E). Participants will only enroll in one part.

A Study of LY2157299 in Participants With Hepatocellular Carcinoma

Study Alias: H9H-MC-JBAK

The purpose of this study is to estimate the median time to progression in participants with hepatocellular carcinoma (HCC) when treated with LY2157299 as monotherapy and in combination with sorafenib or ramucirumab.

A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine

Study Alias: I5Q-MC-CGAW

The purpose of this study is to assess the safety and efficacy of galcanezumab in people with treatment-resistant episodic or chronic migraine.

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis (IXORA-Q)

Study Alias: I1F-MC-RHBQ

The main purpose of this study is to evaluate the efficacy and safety of the study drug ixekizumab compared to placebo in participants with moderate-to-severe genital psoriasis.

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

Study Alias: I4L-MC-ABER

The main purpose of this study is to evaluate the safety and efficacy of the study drug known as LY2963016 as compared to LANTUS® in adults with type 2 diabetes mellitus who are on 2 or more oral antihyperglycemic medications (OAMs).

A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

Study Alias: I6F-MC-JJCB

The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with dexamethasone in participants with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma (T-ALL/T-LBL)

A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)

Study Alias: J1G-MC-LAKA

The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in healthy participants and participants with AD. The study will also investigate how much LY3372993 gets into the bloodstream and test the effects of LY3372993 in participants with AD. The study has two parts: Part A - Healthy participants will receive LY3372993 or placebo. Part A will last up to 17 weeks and Part B - Participants with AD will receive LY3372993 or placebo. Part B will last about 317 days.

A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer

Study Alias: I4C-MC-JTBF

The purpose of this study is to find a recommended schedule and dose range for LY2875358 when given with ramucirumab that may be safely given to participants with cancer. In Part A of this study, escalating doses of LY2875358 will be given in combination with a fixed dose of ramucirumab to evaluate the safety of the combination. After a recommended schedule and dose range of LY2875358 and ramucirumab has been established, Part B of the study will confirm safety and to see how well certain tumors respond to the combination of study drugs.

A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes

Study Alias: I8B-FH-ITSE

The purpose of this study is to see if LY900014 compared to insulin lispro (Humalog), both in combination with insulin glargine or insulin degludec, is safe and effective in participants with type 2 diabetes (T2D).

A Study of Baricitinib (LY3009104) in Adults With Moderate to Severe Atopic Dermatitis (Eczema) (BREEZE-AD2)

Study Alias: I4V-MC-JAHM

The purpose of this study is to evaluate the efficacy and safety of baricitinib as a single drug treatment in participants with moderate to severe atopic dermatitis (eczema).

A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis

Study Alias: I6T-MC-AMAC

The main purpose of this study is to test the hypothesis that treatment with LY3074828 is superior to placebo in providing clinical benefit to participants with moderate to severe ulcerative colitis (UC). This study will also investigate how the body processes the drug.

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Study Alias: I6F-MC-JJCD

The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.

A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

Study Alias: I4T-MC-JVDJ

The main purpose of this study is to evaluate the safety of ramucirumab plus MEDI4736 in participants with locally advanced and unresectable or metastatic gastrointestinal or thoracic malignancies including gastric or gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or hepatocellular carcinoma (HCC)

A Study of LY900014 in Participants With Type 1 Diabetes on Insulin Injection Therapy

Study Alias: I8B-FW-ITRG

The study will investigate how the body processes LY900014 and the effect of LY900014 on blood sugar levels in participants with Type 1 Diabetes on insulin injection therapy. Side effects and tolerability will be documented.

A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)

Study Alias: J1I-MC-GZBB

The main purpose of this study is to learn about the side effects of LY3437943 when given to participants with type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3437943, dulaglutide, or placebo given just under the skin.

A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

Study Alias: J1O-MC-JZHC

The reason for this study is to determine the recommended phase 2 dose of the study drug LY3295668 erbumine in participants with breast cancer that has spread to other parts of the body.

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioblastoma

Study Alias: H9H-MC-JBEF

The main purpose of this study is to evaluate the safety, tolerability, and efficacy of the study drug known as galunisertib in combination with nivolumab in participants with advanced refractory solid tumors and in recurrent or refractory non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC) or glioblastoma.

A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes (PRONTO-T2D)

Study Alias: I8B-MC-ITRN

The purpose of this study is to compare LY900014 to insulin lispro, both in combination with insulin glargine or insulin degludec, in participants with type 2 diabetes (T2D).

A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide

Study Alias: I8F-MC-GPHU

The purpose of this study is to learn more about how tirzepatide affects stomach emptying in overweight/ very overweight participants. Participants include those without diabetes and those with type 2 diabetes.

A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

Study Alias: I4T-MC-JVCZ

The main purpose of this study is to evaluate the efficacy of an alternative dose of ramucirumab in combination with paclitaxel in participants with second-line metastatic or locally advanced, unresectable gastric or gastroesophageal junction adenocarcinoma (GEJ).

A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes

Study Alias: F3Z-MC-IOQY

The purpose of this study is to investigate the user experience of an integrated insulin management system (IIM) in participants with type 1 or type 2 diabetes. The IIM system is comprised of an insulin injection pen with a data transmission module and blood glucose meter which are connected to a mobile phone application. The application will be used to record and track diabetes-data related information.

A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Study Alias: I5B-MC-JGDR

The purpose of this study is to evaluate the safety of ifosfamide when added to olaratumab and doxorubicin in participants with soft tissue sarcoma (STS) that is advanced or has spread to another part(s) of the body.

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis (IXORA-S)

Study Alias: I1F-MC-RHBS

The main purpose of this study is to evaluate the efficacy of the study drug ixekizumab compared to ustekinumab in participants with moderate-to-severe-plaque psoriasis

A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes (AWARD-11)

Study Alias: H9X-MC-GBGL

The purpose of this study is to evaluate the efficacy and safety of investigational doses of once weekly dulaglutide when added to metformin in participants with type 2 diabetes with inadequate blood sugar control.

A Study of LY2801653 in Participants With Advanced Cancer

Study Alias: I3O-MC-JSBA

The purpose of this study is to determine a recommended phase 2 dose of LY2801653 that may be safely given to participants with gastric cancer when taken with ramucirumab.

A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine

Study Alias: H8H-MC-LAHX

The purpose of the study is the measure the levels of lasmiditan in the body of children aged 6 to 17 with migraine. The study also will also examine the safety and tolerability of lasmiditan in children aged 6 to 17 with migraine.

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

Study Alias: I5F-MC-JSCC

The main purpose of this study is to evaluate the safety of the colony-stimulating factor 1 receptor (CSF-1R) inhibitor LY3022855 in combination with durvalumab or tremelimumab in participants with advanced solid tumors.

A Study of LY2951742 in the Prevention of Episodic Migraine (EVOLVE-2)

Study Alias: I5Q-MC-CGAH

The main purpose of this study is to evaluate the efficacy of the study drug known as LY2951742 in participants with episodic migraine.

A Study of LY900014 in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps

Study Alias: I8B-FW-ITRF

The purpose of this study is to investigate how the human body processes LY900014 and its effect on blood sugar levels when it is delivered via an insulin pump to participants with type 1 diabetes mellitus. Side effects and tolerability will be documented.

A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis (COAST-W)

Study Alias: I1F-MC-RHBW

The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in participants with radiographic axial spondyloarthritis (rad-axSpA) who have taken tumor necrosis factor (TNF) inhibitor.

A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)

Study Alias: I3Y-MC-JPBJ

The main purpose of this study is to evaluate the safety and tolerability of abemaciclib in combination with another anti-cancer drug in participants with NSCLC that is advanced or has spread to other parts of the body (stage IV). The study will also investigate how the body processes the combination treatment and how the study drug affects the body. The study will also collect disease-related symptoms and participant-reported pain related to NSCLC.

A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)

Study Alias: F3Z-MC-IOQS

The Automated Insulin Delivery (AID) System is an investigational insulin delivery device being developed for use for participants with diabetes. The purpose of this study is to assess the safety of the AID system and to test whether the AID System functions as it was designed to.

A Study of Lasmiditan in Participants With Migraine

Study Alias: H8H-MC-LAHC

The purpose of this study is to measure how much of the drug gets into the blood stream and how long it takes the body to get rid of it during an acute migraine attack and also during the time between acute migraine attacks.

A Study of LY3361237 in Participants With Systemic Lupus Erythematosus

Study Alias: I9S-MC-BTAB

The main purpose of this study is to learn more about the safety of LY3361237 and any side effects that might be associated with it when given to participants with systemic lupus erythematosis (SLE). LY3361237 will be administered by injections just under the skin.

Evaluation of Galcanezumab in the Prevention of Chronic Migraine (REGAIN)

Study Alias: I5Q-MC-CGAI

The main purpose of this study is to evaluate the efficacy of the study drug known as LY2951742 in participants with chronic migraine

A Study of Abemaciclib (LY2835219) Alone or in Combination with Other Agents in Participants with Previously Treated Pancreatic Ductal Adenocarcinoma

Study Alias: I3Y-MC-JPCJ

The purpose of this study is to evaluate the safety and efficacy of abemaciclib alone and in combination with other drugs versus standard of care in participants with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).

A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis (Spirit-H2H)

Study Alias: I1F-MC-RHCF

The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drugs (DMARD) naive.

A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

Study Alias: I5T-MC-AACD

The purpose of this study is to evaluate the effect of LY3002813 on brain scans, evaluate the safety of LY3002813 by looking at adverse events (side effects) and to look at the effect of LY3002813 on the body. The study is for research purposes only and is not intended to treat any medical condition.

A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC

Study Alias: I4X-MC-JFCQ

The main purpose of this study is to evaluate the safety and efficacy of the combination of necitumumab with pembrolizumab in participants with stage IV NSCLC.

A Study of LY2951742 in Participants With Episodic Cluster Headache

Study Alias: I5Q-MC-CGAL

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as LY2951742 in participants with episodic cluster headaches.

A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

Study Alias: H8H-MC-LAIJ

The reason for this study is to see how effective and safe the study drug known as lasmiditan is in the acute treatment of 4 migraine attacks with or without aura.

Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis

Study Alias: I1F-MC-RHCD

The purpose of this study is to evaluate the safety and efficacy of ixekizumab in pediatric participants with moderate-to-severe plaque psoriasis. Note: the study design may differ if you reside outside of US or Canada, please consult with the appropriate investigator for more details.

A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

Study Alias: I6T-MC-AMAJ

The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.

A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

Study Alias: I8F-MC-GPGH

The purpose of this study is to compare the effect of the study drug tirzepatide to insulin degludec on blood sugar levels in participants with type 2 diabetes.

A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis

Study Alias: I1F-MC-RHCR

The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab in participants with moderate-to-severe plaque psoriasis.

A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma (ANNOUNCE-2)

Study Alias: I5B-MC-JGDL

The main purpose of this study is to evaluate the safety and efficacy of two anti-cancer drugs (gemcitabine and docetaxel) with and without the study drug known as olaratumab in participants with advanced soft tissue sarcoma (STS) or STS that has spread to another part(s) of the body.

A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis (Eczema)

Study Alias: J1B-MC-FRCC

The main purpose of this study is to investigate the safety, tolerability, and efficacy of the study drug known as LY3454738 in healthy participants and participants with atopic dermatitis (eczema). The study has three parts. Each participant will enroll in one part. The study will last 12 to 24 weeks, depending on part.

Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. (ADhere)

Study Alias: J2T-DM-KGAD

The study is designed to evaluate the safety and efficacy of lebrikizumab when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination with TCS treatment for moderate-to-severe atopic dermatitis.

A Study of LY3209590 in Participants With Type 1 Diabetes

Study Alias: I8H-MC-BDCP

The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 1 diabetes.

Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis

Study Alias: H0P-MC-OA03

This study is being done to test the safety and efficacy of LY3556050 for the treatment of osteoarthritis pain.

A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease

Study Alias: I8G-MC-LMDC

The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).

A Study of Enzalutamide and LY3023414 in Men with Prostate Cancer

Study Alias: I6A-MC-CBBD

The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY3023414 in combination with enzalutamide in men with prostate cancer.

A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

Study Alias: I8H-MC-BDCL

The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes.

A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

Study Alias: J2R-MC-YAAB

The main purpose of this study is to learn more about the safety of LY3537021 and any side effects that might be associated with it in healthy participants and participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to check how much LY3537021 gets into the bloodstream and how long the body takes to eliminate it.

A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2)

Study Alias: I4T-MC-JVDE

The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) (liver cancer) and elevated baseline alpha-fetoprotein.

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (BRAVE II)

Study Alias: I4V-MC-JAIA

The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).

Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Chronic Low Back Pain

Study Alias: H0P-MC-BP01

This study is being done to test the safety and efficacy of the study drug LY3016859 for the treatment of chronic low back pain.

Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants with Osteoarthritis

Study Alias: H0P-MC-OA01

This study is being done to test the safety and efficacy of LY3016859 for the treatment of osteoarthritis pain.

A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-BASIS)

Study Alias: I4V-MC-JAHV

The reason for this study is to see if the study drug baricitinib given by mouth is safe and effective in participants with juvenile idiopathic arthritis (JIA) from 2 years to less than 18 years old.

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff (BLAZE-2)

Study Alias: J2X-MC-PYAD

The purpose of this study is to evaluate whether LY3819253 given alone and with LY3832479 prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease – 2019 (COVID-19) in facility staff and residents in skilled nursing and assisted living facilities with a high risk of SARS-CoV-2 exposure. Participants with a high risk of SARS-CoV-2 exposure will receive LY3819253, LY3819253 and LY3832479, or placebo via an injection into a vein. Samples will be taken from the nose. Blood samples will be drawn. To speak with a study representative, call 718-210-9713.

A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis (COAST-Y)

Study Alias: I1F-MC-RHBY

The purpose of this study is to evaluate, in participants having achieved a state of sustained remission, if the ixekizumab treatment groups are superior to the placebo group in maintaining response during the randomized withdrawal-retreatment period in participants with axial spondyloarthritis.

A Study of Mealtime Insulin LY900014 in Participants with Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)

Study Alias: I8B-MC-ITSW

This study is being done to evaluate glycemic control in participants with type 2 diabetes who are taking mealtime insulin LY900014 in combination with long-acting insulin glargine.

A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes

Study Alias: I8B-FH-ITSD

The purpose of this study is to see if LY900014 compared to insulin lispro (Humalog), both in combination with insulin glargine or insulin degludec, is safe and effective in participants with type 1 diabetes (T1D).

A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes

Study Alias: I8B-MC-ITSB

The reason for this study is to compare the study drug LY900014 to insulin lispro (Humalog) in children and adolescents with type 1 diabetes (T1D).

A Real World Study of Bamlanivimab in Participants With Mild-to-moderate Coronavirus Disease 2019 (COVID-19) (BLAZE-5)

Study Alias: J2X-MC-PYAJ

The purpose of this study is to find out whether bamlanivimab is able to stop COVID-19 from getting worse.

Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain

Study Alias: H0P-MC-NP01

This study is being done to test the safety and efficacy of the study drug LY3016859 for the treatment of diabetic peripheral neuropathic pain.

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

Study Alias: J1O-MC-JZHB

The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.

Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Chronic Low Back Pain

Study Alias: H0P-MC-BP03

This study is being done to test the safety and efficacy of the study drug LY3556050 for the treatment of chronic low back pain. This trial is part of the chronic pain master protocol (H0P-MC-CPMP) which is a protocol to accelerate the development of new treatments for chronic pain.

A Study of LY3493269 in Participants With Type 2 Diabetes

Study Alias: J1X-MC-GZHC

The main purpose of this study is to determine the side effects related to LY3493269 in participants with type 2 diabetes.

A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

Study Alias: I6T-MC-AMAH

The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.

A Study of Baricitinib (LY3009104) in Participants With COVID-19 (COV-BARRIER)

Study Alias: I4V-MC-KHAA

The reason for this study is to see if the study drug baricitinib is effective in hospitalized participants with COVID-19.

A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes (AWARD-PEDS)

Study Alias: H9X-MC-GBGC

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of the study drug dulaglutide compared to placebo in pediatric participants with type 2 diabetes. The study duration is approximately 60 weeks.

A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)

Study Alias: I8F-MC-GPGM

The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk.

A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes (SURPASS-2)

Study Alias: I8F-MC-GPGL

The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes.

A Study of LY3023414 in Participants With Advanced Cancer

Study Alias: I6A-MC-CBBA

The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer. The study will also explore the changes to various markers in blood cells and potentially tumor cells. Finally, the study will help document any antitumor activity this drug may have.

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness (BLAZE-1)

Study Alias: J2W-MC-PYAB

The purpose of this study is to measure how well LY3819253 and LY3832479 work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19, via an injection into a vein. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 weeks and includes one required visit to the study site, with the remainder of assessments performed in the home or by phone.